Search | Clinical Trials Finder

Conditions: Hidradenitis Suppurativa (HS)
Interventions: ORKA-002, Placebo; Drug · Other
Lead sponsor: Oruka Therapeutics, Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 12 more

Conditions: Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions: KT-474/Placebo, KT-474; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Pelashield Painguard; Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Hidradenitis Suppurativa
Interventions: secukinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 18
States / cities: Birmingham, Alabama • Rogers, Arkansas • Anaheim, California + 15 more

Conditions: Hidradenitis Suppurativa
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more

Conditions: Hidradenitis Suppurativa
Interventions: AVTX-009 Regimen 1, AVTX-009 Regimen 2, Placebo; Drug
Lead sponsor: Avalo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 36
States / cities: Scottsdale, Arizona • Tucson, Arizona • Northridge, California + 31 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Roflumilast 0.3% topical foam; Drug
Lead sponsor: Harrison Dermatology; Other
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Missouri City, Texas

Conditions: Hidradenitis Suppurativa
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 9 Years to 17 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: Roseville, California • Sacramento, California • Washington D.C., District of Columbia + 8 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Tibulizumab Dose A, Tibulizumab Dose B, Placebo; Biological · Other
Lead sponsor: Zura Bio Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 34
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 30 more

Conditions: Hidradenitis Suppurativa
Interventions: Spesolimab 1200 mg, Spesolimab 600 mg, Placebo matching 600 mg Spesolimab, Placebo matching 1200 mg Spesolimab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 1 more

Conditions: Hidradenitis Suppurativa
Interventions: Mediterranean Diet Counseling, Mediterranean Food Support; Behavioral · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Roflumilast 0.3% topical foam; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hidradenitis Suppurativa (HS)
Interventions: SPY072, Placebo, bimekizumab; Drug
Lead sponsor: Spyre Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 12
States / cities: Irvine, California • Indianapolis, Indiana • Bowling Green, Kentucky + 9 more

Conditions: Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Santa Monica, California • South Miami, Florida • Boston, Massachusetts + 3 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: EVO101; Drug
Lead sponsor: Virginia Clinical Research, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Hidradenitis Suppurativa
Interventions: secukinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 29
States / cities: Rogers, Arkansas • San Diego, California • Whittier, California + 22 more

Conditions: Hidradenitis Suppurativa
Interventions: Home Exercise Program, Short Exercise Program; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 80 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hidradenitis Suppurativa
Interventions: Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 36
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more

Conditions: Hidradenitis Suppurativa
Interventions: AviClear; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Povorcitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 37
States / cities: Phoenix, Arizona • Arkansas City, Arkansas • Fort Smith, Arkansas + 32 more

Conditions: Hidradenitis Suppurativa, Hidradenitis Suppurativa \(HS\), Hidradenitis Suppurativa, Acne Inversa
Interventions: Normal saline, Botulinum toxin type A; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Guilford, Connecticut

Conditions: Hidradenitis Suppurativa
Interventions: Remibrutinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 18
States / cities: Fort Smith, Arkansas • Fremont, California • Los Angeles, California + 14 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Radiated axilla; Radiation
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Cherry Hill, New Jersey • Philadelphia, Pennsylvania

Conditions: Hidradenitis Suppurativa
Interventions: Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 35
States / cities: Birmingham, Alabama • Gilbert, Arizona • Fremont, California + 30 more

Search by objective public record fields.

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

Pelashield™ PainGuard™ vs Restrata® in HS Surgery

This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

Mediterranean Dietary Intervention for HS

The Safety and Efficacy of Roflumilast Foam in HS

A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

Physical Activity in Hidradenitis Suppurativa (HS)

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

Aviclear for Hidradenitis Suppurativa (HS)

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Botulinum Toxin-A for Hidradenitis Suppurativa

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

Radiotherapy for Refractory Hidradenitis Suppurativa

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa